|24.53 0.74 (3.11%)||12-07 16:00|
|Targets||6-month :||30.66||1-year :||34.68|
|Resists||First :||26.25||Second :||29.7|
|Supports||First :||20.67||Second :||17.19|
|MAs||MA(5) :||23.97||MA(20) :||26.56|
|MA(100) :||27.98||MA(250) :||31.16|
|MACD||MACD :||-0.7||Signal :||-0.2|
|%K %D||K(14,3) :||35.9||D(3) :||36.1|
|52-week||High :||42.47||Low :||20.67|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARWR ] has closed above bottom band by 31.5%. Bollinger Bands are 112.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||23.94 - 24.05||24.05 - 24.16|
|Low:||23.07 - 23.2||23.2 - 23.32|
|Close:||23.58 - 23.78||23.78 - 23.97|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||107 (M)|
|Shares Float||104 (M)|
|Held by Insiders||4.9 (%)|
|Held by Institutions||70.7 (%)|
|Shares Short||7,880 (K)|
|Shares Short P.Month||7,130 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||2.52|
|Profit Margin||-85.3 %|
|Operating Margin||-673 %|
|Return on Assets (ttm)||-17.6 %|
|Return on Equity (ttm)||-59.4 %|
|Qtrly Rev. Growth||-49 %|
|Gross Profit (p.s.)||2.26|
|Sales Per Share||2.24|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||0 (M)|
|Price to Book value||9.69|
|Price to Sales||10.94|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|